Is RICHT.BD overvalued or undervalued?

RICHT.BD currently has a P/E ratio of 9.83. Relative to the sector average of 23.30, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Chemical Works of Gedeon Richter Plc stock?

Chemical Works of Gedeon Richter Plc trades on BUD. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of RICHT.BD?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying RICHT.BD protect my money against local inflation?

Many investors in Latin America buy international stocks like RICHT.BD to protect their purchasing power. Because RICHT.BD is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy RICHT.BD shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is RICHT.BD a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well RICHT.BD diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksRICHT.BD

Chemical Works of Gedeon Richter Plc

Ft 12,350.00+Ft 150.00+1.23%

BUD / HUF

Market cap

Ft 2.26T

P/E

9.8

EPS (TTM)

Ft 3.82

Dividend yield

5.31%

Beta

0.58

1Y return

+18.64%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$1.9B2021

$2.1B2022

$2.3B2023

$2.1B2024

$2.8B2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.01Low
Current ratio4.69
Cash ratio1.46
Net margin24.8%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

RICHT.BD9.8
Healthcare sector median23.3
S&P 50022.0

Trades about 58% below its sector, cheaper than its peers on earnings.

Ratios

PEG-2.52
Price to book1.55
EPS (TTM)Ft 3.82
Payout ratio4,053%
FCF yield13.85%

Range & risk

Ft 9380.00Ft 13570.00

Trading in the upper third of its 52-week band

Beta0.58

Profile

What Chemical Works of Gedeon Richter Plc actually does

Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

CEO

Gabor Orban

Employees

11,955

Headquarters

Budapest, BU

Founded

1994-11-09

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save RICHT.BD and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

RICHT.BD has a beta of 0.58, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Chemical Works of Gedeon Richter Plc